Efficacy of intravenous immunoglobulin therapy in acute phase of myasthenia gravis in children
-
- Takeuchi Hirokazu
- Division of Neurology, Saitama Children’s Medical Center, Saitama Department of Pediatrics, (The) Jikei University School of Medicine, Tokyo
-
- Matsuura Ryuki
- Division of Neurology, Saitama Children’s Medical Center, Saitama Department of Pediatrics, (The) Jikei University School of Medicine, Tokyo
-
- Kikuchi Kenjiro
- Division of Neurology, Saitama Children’s Medical Center, Saitama Department of Pediatrics, (The) Jikei University School of Medicine, Tokyo
-
- Takeda Rikako
- Division of Neurology, Saitama Children’s Medical Center, Saitama
-
- Hirata Yuko
- Division of Neurology, Saitama Children’s Medical Center, Saitama Department of Pediatrics, (The) Jikei University School of Medicine, Tokyo
-
- Koichihara Reiko
- Division of Child Health and Human Development, Saitama Children’s Medical Center, Saitama
-
- Hamano Shin-ichiro
- Division of Neurology, Saitama Children’s Medical Center, Saitama
Bibliographic Information
- Other Title
-
- 小児重症筋無力症に対する急性期における免疫グロブリン静注療法の有効性について
Abstract
<p> Objective: We investigated the efficacy of intravenous immunoglobulin (IVIG) therapy in acute phase of myasthenia gravis (MG) in children and the characteristics of patients for whom IVIG was effective. Methods: The study included 17 patients (6 boys) (8 children with ocular and 9 with generalized MG) aged <15 years who were diagnosed with MG, and received more than 1g/kg of IVIG therapy in acute phase between April 1, 2010 and March 31, 2022. Children in whom the MG activities of daily living score improved by ≥1 within 14 days after IVIG therapy commencement were considered to show a successful response to therapy Those in whom IVIG therapy was effective underwent post-treatment follow-up. Results: Median age at disease onset was 6.0 (0.9-13.9) years, and IVIG therapy in acute phase was administered at median age 6.9 (1.1-14.1) years. IVIG therapy was effective in 8 patients, with significantly more generalized MG in the effective cases (p=0.02). Among patients in whom IVIG therapy was effective, one patient achieved complete remission without medication for >2 years. Complete remission without medication for >2 years after treatment completion was achieved in four patients who responded to IVIG therapy in acute phase and received maintenance IVIG therapy. Conclusions: The efficacy of IVIG therapy in acute phase was higher in children with generalized MG than in those with ocular MG. When IVIG therapy in acute phase is effective, the use of steroids may be avoided or reduced by shifting to maintenance IVIG therapy.</p>
Journal
-
- NO TO HATTATSU
-
NO TO HATTATSU 56 (2), 119-124, 2024
The Japanese Society of Child Neurology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390017965055070208
-
- ISSN
- 18847668
- 00290831
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed